Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611130, China.
Tianjin University of Traditional Chinese Medicine, Tianjin 3016172, China.
Biomed Res Int. 2022 Apr 28;2022:2775434. doi: 10.1155/2022/2775434. eCollection 2022.
To explore the mechanism of Dahuang Fuzi decoction in the treatment of incomplete intestinal obstruction (IIO) based on network pharmacology and molecular docking.
The chemical components of Rhubarb, Aconite, and Asarum were searched by the Traditional Chinese Medicine Systems Pharmacology database, where the possible active components were screened by oral bioavailability and drug likeness as filtering indicators. The relevant targets in the Swiss Target Prediction database were obtained according to the structure of the chemical components confirmed by the PubChem database. Disease targets of IIO were collected using GeneCards and OMIM databases. We obtained the cross-target using VENNY to capture the common targets. PPI analysis was performed on the intersection genes combined with Cytoscape 3.7.2. Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were carried out by David database. The core targets and active ingredients were molecularly docked through AutoDock Vina software to predict the detailed molecular mechanism of Dahuang Fuzi decoction for treating IIO.
There are 45 active components in Dahuang Fuzi decoction, with 709 corresponding targets, 538 IIO targets, and 97 common targets, among which kaempferol, deltoin, and eupatin are the main active ingredients. 10 core targets were obtained by protein-protein interaction network analysis. Through GO enrichment analysis, it was found that Dahuang Fuzi decoction may be involved in biological processes such as signal transduction, anti-apoptosis, promotion of gene expression, regulation of cell proliferation, and differentiation. Besides, KEGG pathway analysis revealed that it mainly relates to PI3K-AKT signal pathway and HIF-1 signal pathway, etc. Molecular docking results showed that the active ingredients of Dahuang Fuzi decoction possess a good binding activity with the core targets.
Dahuang Fuzi decoction may act on target genes such as TNF, IL6, AKT1, VEGFA, SRC, EGFR, and STAT3 through active ingredients such as kaempferol, deltoin, and eupatin to regulate signaling pathways such as PI3K-AKT and HIF-1 and reduce the expression of various inflammatory factors such as TNF-, IL-6, iNOS, and COX-2 to play a role in the treatment of IIO.
基于网络药理学和分子对接技术探讨大黄附子汤治疗不完全性肠梗阻(IIO)的作用机制。
利用中药系统药理学数据库(TCMSP)检索大黄、附子和细辛中的化学成分,以口服生物利用度和类药性为筛选指标,筛选出潜在的活性成分。根据 PubChem 数据库中化学结构确认的化合物结构,从 Swiss Target Prediction 数据库中获得相应的靶标。使用 GeneCards 和 OMIM 数据库收集 IIO 的疾病靶标。使用 VENNY 软件获取共同靶标,捕获共有靶标。将交叉靶标与 Cytoscape 3.7.2 软件相结合进行 PPI 分析。通过 David 数据库进行基因本体(GO)功能富集分析和京都基因与基因组百科全书(KEGG)通路富集分析。使用 AutoDock Vina 软件对核心靶标和活性成分进行分子对接,预测大黄附子汤治疗 IIO 的详细分子机制。
大黄附子汤含有 45 种活性成分,对应 709 个靶标,538 个 IIO 靶标和 97 个共同靶标,其中山柰酚、deltoin 和 eupatin 是主要的活性成分。通过蛋白质-蛋白质相互作用网络分析得到 10 个核心靶标。通过 GO 富集分析发现,大黄附子汤可能参与信号转导、抗细胞凋亡、促进基因表达、细胞增殖和分化等生物学过程。此外,KEGG 通路分析表明,其主要与 PI3K-AKT 信号通路和 HIF-1 信号通路等相关。分子对接结果表明,大黄附子汤的活性成分与核心靶标具有良好的结合活性。
大黄附子汤可能通过山柰酚、deltoin 和 eupatin 等活性成分作用于 TNF、IL6、AKT1、VEGFA、SRC、EGFR 和 STAT3 等靶标,调节 PI3K-AKT 和 HIF-1 等信号通路,降低 TNF-、IL-6、iNOS 和 COX-2 等多种炎症因子的表达,从而发挥治疗 IIO 的作用。